Istaroxime

Drug Profile

Istaroxime

Alternative Names: Debio 0614; PST 2744; ST 2744

Latest Information Update: 09 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sigma-tau SpA
  • Developer CVie Therapeutics
  • Class Amines; Androstanols; Cardiotonics; Heart failure therapies; Ketosteroids; Oximes; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Decompensated heart failure

Most Recent Events

  • 05 Aug 2016 CVie Therapeutics and ScinoPharm agree to co-develop istaroxime in Taiwan for Chronic heart failure
  • 04 Dec 2015 CVie Therapeutics is planning a phase II trial in Decompensated heart failure (In adults, In the elderly) in China (NCT02617446)
  • 17 Aug 2015 Phase-II development is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top